Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 8Neoplasms 7Colorectal Neoplasms 5Recurrence 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Radiation Pneumonitis 2Peritoneal Neoplasms 2Mesothelioma, Malignant 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasm Metastasis 1

Interventions

Paclitaxel 114Carboplatin 114Cisplatin 45Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28liposomal doxorubicin 27Bevacizumab 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15sargramostim 12Hyperthermic Intraperitoneal Chemotherapy 12olaparib 11Chemotherapy, Adjuvant 10Surgical Procedures, Operative 9Etoposide 9oregovomab 8mirvetuximab soravtansine 8Nivolumab 8Amifostine 8Therapeutics 7Melphalan 7Erlotinib Hydrochloride 7rucaparib 6aldesleukin 6Oxaliplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ovarian Epithelial × nintedanib × Clear all
NCT01669798 2018-10-16

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Duke University

Phase 2 Completed
32 enrolled 19 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡